Prem Watsa
Fairfax Financial Holdings
Prem Watsa ARRAY BIOPHARMA INC stake
total: 291
Fairfax Financial Holdings ARRY-OLD trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2019 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2019 Q3
According to 2026 Q2 report, Prem Watsa doesn't hold any ARRAY BIOPHARMA INC (ARRY-OLD) shares. To date, the estimated cost basis is nearly $46.29 for "buy" trades and estimated average "sell" price is $46.29. Fairfax Financial Holdings first purchased ARRY-OLD in 2019 Q2, initially acquiring 27,500 shares. Since the initial investment in ARRAY BIOPHARMA INC (ARRY-OLD), Fairfax Financial Holdings has made 1 more transaction.
When did Prem Watsa sell ARRAY BIOPHARMA INC (ARRY-OLD)?
Prem Watsa sold off the entire ARRAY BIOPHARMA INC (ARRY-OLD) position in 2019 Q3.
When did Prem Watsa buy ARRAY BIOPHARMA INC (ARRY-OLD)?
Prem Watsa first invested in ARRAY BIOPHARMA INC (ARRY-OLD) in 2019 Q2 at the reported quarter-end price of $46.29 per share.
What's the cost basis of Fairfax Financial Holdings's ARRY-OLD stake?
The estimated cost basis for ARRAY BIOPHARMA INC (ARRY-OLD) stake is around $46.29 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $46.29
- Weighted AVG sell price:
- $46.29
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.